The Patent Reform Act of 2007 is stirring debate, not only in both houses of Congress, but also within the pharmaceutical, biotechnology, software, and electronics industries. Nanotechnology companies too must be aware of what is at stake. In this article, Washington, DC patent attorney Stephen Maebius discusses the potential impact of the pending legislation on nanotechnology. The proposed changes would affect everything from who is entitled to receive a patent (first-to-invent or first-to-file) all the way to how infringement damages are calculated. Because they rely so heavily on the value of their patent portfolio, nanotech companies should form a collective voice to communicate a position in this important debate.
Author(s)
Related Insights
Watch On-Demand
Upcoming
Events
Get Anytime Access to Continuing Legal Education and Business Programming
Our new LearningLab: On-Demand Hub offers a growing library of continuing legal education (CLE) and business-focused legal insights you can now access anytime, anywhere.
October 27, 2026
Upcoming
Events
Federal Administrative Sanctions: Suspensions, Revocations, Exclusions, and Civil Monetary Penalties
Foley partner Judy Waltz, chair of the firm’s Health Care Practice Group, is speaking at the upcoming HCCA Healthcare Enforcement Compliance Conference in the session “Federal Administrative Sanctions: Suspensions, Revocations, Exclusions, and Civil Monetary Penalties.”
October 9, 2026
Upcoming
Events
22nd Annual IP Conference
Foley & Lardner LLP is back in Boston for our 22nd Annual IP Conference! Join us on Friday, October 9, 2026, for a full day of insightful discussions led by industry voices from across the corporate and intellectual property landscape. This premier event will explore emerging trends, best practices in IP management, and key legal considerations, providing a valuable opportunity to: